Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:05:32 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:AMGN - AMGEN INC - https://www.amgen.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AMGN - Q9.0383.01·384.000.1384.32+16.524.53,840.21,457,28063,137369.99  385.12  368.90374.90  261.4319:57:17Feb 0315 min RT 2¢

Recent Trades - Last 10 of 63137
Time ETExPriceChangeVolume
19:57:17Q383.8016.001
19:56:19Q383.229715.429710
19:52:11Q383.677615.877625
19:51:42Q383.231515.43155
19:50:35Q383.078515.27851
19:46:12Q383.0215.225
19:40:17Q383.0115.211
19:38:21Q383.8016.0050
19:38:04Q383.0115.212
19:30:27Q383.8016.004

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-03 16:01U:AMGNNews ReleaseAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
2026-01-28 16:01U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
2026-01-07 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2026-01-06 09:00U:AMGNNews ReleaseAMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
2025-12-19 14:23U:AMGNNews ReleaseAMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
2025-12-11 18:09U:AMGNNews ReleaseFDA APPROVES UPLIZNA(TM) FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
2025-12-09 16:01U:AMGNNews ReleaseAMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
2025-11-24 16:10U:AMGNNews ReleaseAMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
2025-11-24 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
2025-11-19 16:01U:AMGNNews ReleaseFDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA(TM) IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
2025-11-08 10:10U:AMGNNews ReleaseAMGEN'S REPATHA(TM) CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
2025-11-04 16:01U:AMGNNews ReleaseAMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
2025-10-31 16:01U:AMGNNews ReleaseAMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
2025-10-31 09:00U:AMGNNews ReleaseAMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
2025-10-29 16:01U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
2025-10-17 16:00U:AMGNNews ReleaseFDA APPROVES TEZSPIRE(TM) FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
2025-10-06 20:50U:AMGNNews Release/C O R R E C T I O N -- Amgen/
2025-10-06 09:00U:AMGNNews ReleaseAMGEN MAKES REPATHA(TM) AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
2025-10-02 09:00U:AMGNNews ReleaseLANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
2025-09-26 09:00U:AMGNNews ReleaseAMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS